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Overexpression of human NADPH:cytochrome c (P450)
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tirapazamine (SR 4233) and RSU 1069
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Summary P450 reductase (NADPH: cytochrome c (P450) reductase, EC 1.6.2.4) plays an important role in the reductive activation of the
bioreductive drug tirapazamine (SR4233). Thus, in a panel of human breast cancer cell lines, expression of P450 reductase correlated with
both the hypoxic toxicity and the metabolism of tirapazamine [Patterson et al (1995) Br J Cancer 72: 1144-1150]. To examine this
dependence in more detail, the MDA231 cell line, which has the lowestactivity of P450 reductase in our breast cell line panel, was transfected
with the human P450 reductase cDNA. Isolated clones expressed a 78-kDa protein, which was detected with anti-P450 reductase antibody,
and were shown to have up to a 53-fold increase in activity of the enzyme. Using six stable transfected clones covering the 53-fold range of
activity of P450 reductase, it was shown thatthe enzyme activity correlated directly with both hypoxic and aerobictoxicity oftirapazamine, and
metabolism of the drug under hypoxic conditions. No metabolism was detected under aerobic conditions. For RSU1069, toxicity was also
correlated with P450 reductase activity, but only under hypoxic conditions. Measurable activity of P450 reductase was found in a selection of
14 primary human breast tumours. Activity covered an 18-fold range, which was generally higher than that seen in cell lines but within the
range of activity measured in the transfected clones. These results suggest that if breast tumours have significant areas of low oxygen
tension, then they are likely to be highly sensitive to the cytotoxic action of tirapazamine and RSU 1069.
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It is now well established that regions of low oxygen tension
(hypoxia) can exist in many human solid tumours and that this
hypoxia can sometimes predispose to failure of some treatments
with radiotherapy (Hoeckel et al, 1996). Oneofthe reasons forthis
failure is likely to be the inherent radiation resistance of hypoxic
cells. One strategy being developed to overcome this problem is
via the use ofdrugs that will selectively kill hypoxic cells (Adams
and Stratford, 1986, 1994; Zeman et al, 1986; Kennedy, 1987;
Brown and Siim, 1996; Denny etal, 1996). This approach involves
the exploitation of various biochemicla processes that, at low
oxygen tensions, can result in selective reductive activation of a
prodrug to give cytotoxic species (Workman and Stratford, 1993).
Compounds that have been found to show substantial differential
killing ofhypoxic vs oxic cells include the 2-nitroimidazole RSU
1069 and the benzotriazene-di-N-oxide SR4233, tirapazamine
Stratford and Stephens 1989; Brown 1993; Adams and Stratford,
1994), with the latter drug currently undergoing phase III clinical
investigation.
As indicated above, the major rationale for the development of
bioreductive drugs has been the presence of hypoxia in tumours.
However, for these agents to be effective, they require metabolic
activation, catalysed by the cellular complement of reductase
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enzymes. Thus, it has been proposed that hypoxic cells could
be more effectively targeted if differences in the levels of the
reductases in various cell types were taken into account to
direct appropriate agents to particular human tumours based on
their enzymology (Workman and Walton, 1989;Workman and
Stratford, 1993).
Patterson et al (1995) examined the possible application of the
enzyme-directed approach to the development of tirapazamine.
The metabolism of this agent was suggested to be dependent on
the presence of P450 reductase (Walton et al, 1989, 1992). In a
panel of six breast cancer cell lines with a sixfold range in P450
reductase activity, metabolism correlated directly with enzyme
activity and, in addition, expression of P450 reductase also
strongly correlated with the hypoxic toxicity ofthe drug (Patterson
et al, 1995). In the present work, this dependence is examined in
more detail. To do this, the cell line from the panel ofsix described
by Patterson et al (1995) that showed the lowest level of P450
reductase activity, i.e. MDA 231, was transfected with a DNA
construct containing the human gene encoding this enzyme. A
range of stable transfected clones were isolated and tested, firstly,
for their sensitivity to tirapazamine under aerobic or hypoxic
conditions and, secondly, for their ability to metabolize the drug.
This approach would confirm the importance of P450 reductase
for activation and toxicity of tirapazamine and also eliminate the
possibility that other reductases co-regulated with P450 reductase
contributed to the original findings of Patterson et al (1995). In
addition, in the current study, the panel ofstable transfected clones
were also used as a model system to evaluate the possible contri-
bution of P450 reductase to the hypoxic toxicity of the bioreduc-
tive drug RSU 1069.
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Finally, to put this study in a clinical context and to extend the
validity ofthe enzyme-directed approach to bioreductive drug devel-
opment, measurements were made of P450 reductase activity in a
series of primary human breast tumour biopsies. These measure-
ments are compared directly with those made in breast cancer cell
lines and in the MDA 231-transfected clones described here.
MATERIALS AND METHODS
Chemicals
Tirapazamine, SR 4317, SR4330 and RSU 1069 were synthesized
in house using previously described methods (Seng and Ley, 1972;
Adams et al, 1984). NADPH was purchased from Boehringer
Mannheim (Lewes, UK), HPLC grade methanol was purchased
from Merck (Lutterworth, UK). All other reagents were of
analytical grade and were purchased from Sigma (Poole, UK).
Tissue culture media was obtained from ICRF (Clare Hall Labs,
UK) and fetal calf serum from Sigma.
Cells and culture
Growth conditions for the six human breast tumour cell lines used
in this work have been described previously (Houlbrook et al,
1994; Patterson et al, 1995). All cell lines were maintained in
exponential growth phase in RPMI 1640 medium (except for
SKBr-3 cells, which were maintained in Dulbecco's modified
Eagle medium), supplemented with 2 mm glutamine and 10%
(v/v) fetal calf serum.
Plasmid construction
The cDNA for human P450 reductase was kindly provided by
Professor CR Wolf, University of Dundee, Scotland. Full length
cDNA (2.4 kb), originally isolated from human skin fibroblasts
(Shephard et al, 1992), was subcloned into the pTZ19R bacterial
vector. Restriction enzyme digest with EcoRI and Sail (Gibco
BRL) allowed the orientation-specific ligation of the cDNA into
the multiple cloning region of the retroviral vector pBabe/Puro
(Morgenstern and Land, 1990). The Moloney murine leukaemia
virus LTR's promoter drives transcription ofthe inserted gene and
has been demonstrated to be more efficient than most internal
promoters in a number of cell types (Osborne and Miller, 1988;
Wilson et al, 1988). The pac gene, under the control of the SV40
early gene promoter, confers resistance to the aminoacyl nucleo-
side antibiotic, puromycin. The ATG-gag sequences necessary for
the high-titre characteristics of the pBabe vector, when packaged
into a retroviral system, does not influence expression of an
inserted gene at the level oftranslation.
Transfections and clonal selection of MDA 231 cells
Cells in exponential growth were harvested with a cell scraper,
washed and resuspended in phosphate 'cytomix' buffer (Van den
Hoff et al, 1992) to increase cell survival after electroporation.
Approximately S x 106 cells were mixed with 10 jig of linearized
pBabe/Red vector and electroporated. Cells were plated at low
density and 48 h later were exposed to 3 jig ml-' puromycin.
Selection was maintained for at least 8 weeks. Individual colonies
were isolated and samples of each were grown on glass coverslips
forsubsequent confocal microscopic examination. Cell monolayers
were washed, fixed in 1:1 acetone-ethanol, blocked with 0.1%
bovine serum albumin (BSA) and incubated with anti-human P450
reductase polyclonal antibody (1:100 dilution). Anti-rabbit IgG
FHTC-conjugated secondary antibody was used (1:1000 dilution) to
visualize theuniformity and subcellular distribution ofthe antibody
binding. The pre-screening of clonal lineages on glass coverslips
using immunohistochemical analysis avoided the unnecessary
expansion of the non-expressing clones for subsequent enzyme
activity assays. Positive clones were further assessed foruniformity
by similar anti-P450 reductase antibody staining using flow cyto-
metric single-cell analysis. Those ofapparent single-cell parentage
were expanded for enzyme activity analysis and subsequent drug
sensitivity work.
Cell lysates and primary breast biopsy sample
preparation
Initial in vitro experiments were conducted using S-9 fractions for
NADPH:cytochrome c (P450) reductase activity analysis of the
clonal lines. Cells in exponential growth phase were washed twice
with phosphate-buffered saline (PBS) and harvested using a sterile
cell scraper. After centrifugation at 100g for 8 min (4°C), pellets
were taken and wvashed in ice-cold hypotonic nuclear buffer A
(10 mm HEPES/potassium hydroxide pH 7.4, 1.5 mm magnesium
chloride, 10 mm potasium chloride, 0.05 mM DTT). After repel-
leting, cells were suspended in 1.0 ml of nuclear buffer A and
allowed to stand for 10 min at 4°C. Suspensions were sonicated
using a MSE Soniprep 150 for 3 x 5 s at a nominal frequency of
23 kHz and an oscillation amplitude of between 5 and 10 jim.
Samples were placed on ice between each sonication. The suspen-
sions were allowed to stand on ice for a further 10 min and then
centrifuged at 7800g for 15 min at 4°C. The resulting lysate was
removed and stored in liquid nitrogen until required. The protein
concentration ofthe cell lysates was determined using the Bio-Rad
protein dye assay (Bradford, 1976) using a Sigma BSA standard.
The fractionation technique for the breast tumour biopsy tissue
samples was different to the standard S-9 lysate preparation.
Tissue was cut up with surgical scissors under liquid nitrogen,
homogenized in 10 mM HEPES, 1 mM EDTA, 0.5 mm benzamide,
0.5 mM phernylmethylsulphonyl fluoride, 1 jig mll trypsin
inhibitor (pH 7.4) (4°C) at a ratio of 1 g of tissue per 20 ml of
buffer and was sonicated as described above. An initial 1600g
spin (4°C) was used to remove excess cellular debris, and the
resulting supernatant was spun at 105 000g for 45 min (2°C).
Membrane pellets were dried and resuspended (with the aid of
homogenization) in Tris-buffered saline (pH 7.4) containing 20%
glycerol. In order to directly compare the P450 reductase activities
seen in the clinical tumour biopsy samples with the in vitro cell
lines, identical membrane preparations were performed using a
representative set ofboth the original panel ofbreast cell lines and
the P450 reductase transfected MDA 231 clonal lines.
Characterization of MDA 231 derived clonal lines
P450 reductase activity was determined spectrophotometrically as
the NADPH-dependent reduction of cytochrome c. Each incuba-
tion comprised 400 jl of cytochrome c (final concentration
50 jM), 100 jl of 10 mm potassium cyanide (final concentration
1 mM) and 10-300 jg lysate protein (10-100 jil volume) made up
to 0.98 ml with 100 mm phosphate buffer, pH 7.6. The reaction
was equilibrated to 37°C and was initiated by addition of 20 jl of
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Figure 1 Confocal microscopy showing distribution of P450 reductase in (A) wild-type, untransfected MDA 231 cells and (B) a mixed population of stable
transfectants before clonal selection
Table 1 MDA-231 P450 reductase-transfected cell lines: determination of key characteristics for each clonal lineage
Cell line NADPH:cytochrome P450 NADH:cytochrome b5 NAD(P)H:DT- Total intracellular In vitro doubling time
reductase reductase diaphorase glutathione ± s.d.
± s.d. ± s.d. ± s.d. ± s.d.
(nmol cyt c min-1 mg-') (nmol cyt c min-' mg-') (nmol cyt c min-' mg-') (nmol 10-6 cells) (h)
Parental 4.5 ± 2.4 42.9 ± 5.2 36.6 ± 35.3 3.6 ± 3.0 23.0 ± 3.0
Rd-06 25.3 ± 3.6 56.3 ± 6.2 7.8 ± 2.1 4.3 ± 1.5 22.7 ± 3.7
Rd-09 40.6 ± 7.8 40.1 ± 2.4 37.8 ± 14.3 2.4 ± 1.9 24.0 ± 2.9
Rd-16 71.2 ± 5.4 39.4 ± 2.4 9.5 ± 7.9 5.7 ± 1.6 22.2 ± 3.7
Rd-22 100.1 ± 17.1 36.2 ± 8.6 6.3 ± 2.4 5.0 ± 2.2 23.3± 1.9
Rd-42 189.6 ± 31.6 42.3 ± 4.7 12.1 ± 13.2 1.9 ± 0.4 24.6 ± 3.4
Rd-53 239.0 ± 19.7 45.1 ± 5.4 36.3 ± 25.9 3.8± 1.3 23.9+ 4.1
10 mm NADPH to the test cuvette (final concentration 200gM),
and the rate of reduction of cytochrome c was monitored at
550 nm for 3 min against a blank without NADPH. Initial rates of
reaction were based on an extinction coefficient of 21 mm-' cm-
calculated and expressed as nmol cytochrome c reduced per min
per mg oflysate protein.
DT-diaphorase activity was determined spectrophotometrically
as the dicoumorol-inhibitible component of the NADH-dependent
reduction of cytochrome c (Robertson et al, 1994). Activity was
expressed as nmol cyt.c reducedmin-' mg-' S-9protein. Cytochrome
b5 reductase activity was determined spectrophotometrically as the
pHMB-inhibitable component ofthe NADH-dependent reduction of
cytochrome c at 37°C (Barham et al, 1996). Results were expressed
as nmol cyt.c reduced min-' mg-' S-9 protein. Total glutathione was
determined as the NADPH-dependent reduction of5,5'-dithiobis(2-
nitrobenzoic acid) when supported by excess exogenous glutathione
reductase (Griffith, 1980). Levels were determined from known
standard glutathione concentrations and were expressed as nmol
glutathione per 106 cells.
In vitro doubling times of cells in exponential growth were
calculated foreach ofthe MDA231 clonal cell lines using the MTT
assay. This is based on the ability of viable cells to convert a
soluble tetrazolium salt, MTT, into purple formazan crystals
(Mossman, 1983). Parallel 96-well plates containing cells seeded
at a density of 103 per well were incubated for up to 8 days. At
daily intervals, plates were assayed for formazan production and
the cell number was derived from a standard curve of optical
density vs cell number, which was generated for each day.
Drug sensitivity
Dose-response curves were determined using the MTT prolifera-
tion assay. Values of IC50, the concentration of drug required to
reduce optical density by 50% compared with the untreated
controls, were used as the measure ofcellular sensitivity to a given
treatment. Previous experiments with tirapazamine and RSU 1069
have shown thatresults obtained with this assay correlate well with
the clonogenic cell-survival method (Stratford and Stephens,
1989) Drug exposures were 3 h under hypoxic and 3 or 96 h under
aerobic conditions. Total growth time before assay with MTT was
96 h. Experimental details differ from those previously described
(Patterson et al, 1995), in that all hypoxic exposures were
conducted under conditions ofcatalyst-induced anoxia (< 1 p.p.m.
oxygen). All plastics and media were preincubated in anoxia for
24 h before use to remove residual oxygen. The value of IC50 in
wild-type MDA 231 cells treated with tirapazamine under these
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extremely hypoxic conditions did not differ significantly from that
reported in our previous work (Patterson et al, 1995). The IC50
values quoted in Tables 2 and 3 are the means of at least five
independent experiments conducted on different days.
Metabolism of tirapazamine by cell lysates
Incubations were carried out in air or under nitrogen at 37°C
(Patterson et al, 1995). Briefly, the 500-gl incubation volume
comprised 100 p1 of cell membrane fraction (maximum final
protein concentration of 1.5 mg ml-'), 100gl of NADPH (5 mM
dissolved in incubation buffer, giving a final incubation concentra-
tion of 1 mM) and 280 g1 of incubation buffer (0.2 M potassium
phosphate buffer, pH 7.4). The reaction was started by addition of
20 gl of tirapazamine (50 mm dissolved in dimethyl sulphoxide
(DMSO) to give a final incubation concentration of 2 mM) and
was stopped after 40 min by addition of methanol. Formation of
SR4317 and SR4330 in the incubation samples was determined
by isocratic reverse-phase HPLC (Walton and Workman, 1990;
Patterson et al, 1995). Three preparations for each cell line were
incubated, each in duplicate, with duplicate analyses.
Statistical analysis
The data were analysed using the standard model for a linear func-
tional relationship with sampling errors in both variables. The data
were logarithmically transformed, and the pooled variance ofeach
data set was calculated. It is assumed that the random sampling
errors are normally and independently distributed with zero means
and variances inversely proportional to the sample size. For statis-
tical analysis of any two data sets, the model is fitted to the obser-
vations by the method of weighted least squares, each sample
mean being weighted in direct proportion to the sample size. The
statistical goodness-of-fit for any two data sets was tested by
calculating the weighted mean-square deviation of the observa-
tions for mean xn and mean y,, from the fitted model and by
comparing this mnean-square with the pooled variance within
samples by a variance-ratio test. The statistical significance of the
estimate of the slope ofthe straight line ofbest fit was tested by a
Student's t-test.
RESULTS
Expression of NADPH:cytochrome c (P450) reductase
The linearized pBabe/Red expression vector was introduced by
electroporation into the human breast adenocarcinoma cell line
MDA231. Stable clones were selected by long-term incubation
in puromycin (3 ,ug ml-'), and homogeneous populations were
expanded for more detailed characterization. Western blot analysis
using a polyclonal antibody raised against recombinant P450
reductase revealed a single band with an apparent molecular
weight of 78 kDa, which co-migrated with endogenous P450
reductase. Subcellular distribution of this immunoreactive protein
was examined by confocal microscopy. An example is given in
Figure 1, which shows the protein to be cytoplasmic with an
apparent reticular localization. No elevated nuclear staining could
be seen in any of the clonal lines, although this observation alone
may not exclude the possibility that a small proportion of the
protein is localized to the nuclear compartment.
Table 2 MDA-231 :P450 reductase-transfected breast cancer cell lines:
response to tirapazamine under aerobic or hypoxic conditions
Cell line Tirapazamine Differential
(IC50 gM ± s.d.) toxicitya
96-h Aerobic 3-h Aerobic 3-h Hypoxic
exposure exposure exposure
Parental 34.2 ± 3.9 615 ± 104 22.6 ± 3.6 25.8
Rd-06 18.6±5.6 329±45 15.1 ±4.6 21.8
Rd-09 13.6± 1.8 258± 120 8.1 ± 1.0 31.9
Rd-16 4.0 ± 1.3 72.6 ± 20.0 3.3 ± 0.8 22.0
Rd-22 3.1 ± 1.3 84.4±21.2 3.5±0.8 24.1
Rd-42 1.5 ± 0.4 40.7± 13.1 2.1 +0.6 19.4
Rd-53 2.4 ± 0.8 50.6 ± 12.3 2.6 ± 1.0 19.5
aRatio of 3-h IC values of air/nitrogen. 50
Table 3 MDA-231: P450 reductase-transfected breast cancer cell lines:
response to RSU 1069 under aerobic or hypoxic conditions
Cell line RSU 1069 Differential
(lC.o gM ± s.d.) toxicitya
96-h Aerobic 3-h Aerobic 3-h Hypoxic
exposure exposure exposure
Parental 22.0 ± 5.6 280 ± 62 176 ± 39 1.6
Rd-06 34.7 ± 8.1 289 ± 47 239 ± 44 1.2
Rd-09 ND ND ND -
Rd-16 14.6±5.1 269±66 38.8± 10.8 6.9
Rd-22 18.1 ± 8.3 258 ± 111 19.0 ± 5.3 13.5
Rd-42 23.8± 5.1 196 ± 47 20.3 ± 7.0 9.7
Rd-53 ND ND ND -
aRatio of 3-h IC values of air/nitrogen.
Characterization of the clonal lines
After transfection, 86 puromycin-resistant colonies were isolated,
ofwhich 21 were found to overexpress P450 reductase. A panel of
six clones, representing the broad spectrum of activities seen, was
selected for further analysis. Elevation in P450 reductase activity
above that ofthe parental cell line ranged from 5.6- to 53-fold and
these changes in activity in each clone were constant over a period
of at least ten passages. For each clonal line, the level ofNADPH-
dependent P450 reductase activity, measured in lysates from up
to eight concurrent passages (i.e. passages 2 through 10; at least
duplicate measurements per passage) is given in Table 1.
Comparative analysis of these clonal lines revealed no systematic
differences in any of the other parameters examined, including
doubling time, DT-diaphorase activity, NADH:cytochrome b5
reductase activity and total glutathione levels.
Bioreductive drug sensitivity
The toxic effect of either tirapazamine or RSU 1069 on the P450
reductase-transfected lines was determined in two types ofexperi-
ment. Firstly, by growing cells in air for 96 h in the presence ofthe
drug and, secondly, by exposing cells to drug for 3 h under aerobic
or hypoxic conditions. The data for each drug are summarized in
Tables 2 and 3.
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Figure 2 Dependence ofICSO values, derived by MTT assay of the transfected MDA 231 clones exposed to (A) tirapazamine or (B) RSU1069 for 96 h in air,
on P450 reductase activity. Bars indicate standard deviations
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Figure 3 Dependence of ICSO values of the transfected MDA 231 clones exposed to tirapazamine for 3 h under aerobic (0) or hypoxic (0) conditions, on P450
reductase activity. Bars indicate standard deviations
There was a clear relationship between S-9 fraction P450 reduc-
tase activity and tirapazamine toxicity in clonal cell lines after
chronic (96 h) exposure in air (Figure 2A). The highest toxicity
(lowest value ofIC50) occurred in the clones with the highest eleva-
tion in P450 reductase activity. The value of slope derived from
this data is -1.38 ± 0.26 (P = 0.003). In contrast, RSU 1069 sensi-
tivity showed no relationship to P450 reductase activities under
chronic aerobic exposure conditions: slope value = -15.4 ± 26.8 (P
= 0.61) (Figure 2B).
The importance of P450 reductase in the activation and toxicity
of tirapazamine and RSU 1069 was characterized further by
carrying out acute (3 h) exposure to drug under aerobic and
hypoxic conditions. The dependence of IC50 for tirapazamine and
RSU 1069 on P450 reductase activity is shown in Figures 3 and 4
respectively. Under hypoxic conditions, there was a highly signifi-
cant relationship between intracellular enzyme activity and toxi-
city for both drugs; the tirapazamine slope value being -1.83 +
0.31 (P = 0.0019) compared with that of RSU 1069, the slope
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value being =-1.61 ± 0.22 (P = 0.018). Aerobic toxicity at 3 h also Tirapazamine metabolism
showed such a dependency for tirapazamine (slope value = - 1.52
± 0.30; P = 0.0041), which contrasts with the modest and non- In order to confirm that overexpression of P450 reductase
significant aerobic sensitization observed for RSU 1069 (slope conferred elevated metabolism oftirapazamine in the clonal lines,
value =-14.8 +9.2; P=0.11). we measured the rate at which cell lysates (membrane prepara-
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Table 4 Response of Rd53 to MMC and POR under aerobic and hypoxic
conditions: sensitivity to MDA231 cells and the transfected clone Rd53
Mitomycin C Porfiromycin
(IC.0jmol dm-3) (IC.) jnmol dm-3)
Cells Air Hypoxia Air Hypoxia
MDA-231 wt 10.6 3.7 1100 70
Rd-53 2.5 0.7 180 9.3
Fold sensitization
Wt/Rd-53 ratio 4.2 5.5 6.1 7.5
tions) reduced tirapazamine to its two-electron reduced product SR
4317 under hypoxic conditions. No formation ofthe deoxygenated
four-electron reduced product SR 4330 was detected in these
experiments. A plot of P450 reductase activity in the clonal cell
lines vs the rate of SR 4317 formation catalysed by membrane
preparations of a representative range of the clonal lines, with
NADPH provided as the electron source, is given in Figure 5. It
can be seen from these data that there is a strong correlation (slope
value = 3.31 ± 0.43; P = 0.0015) between P450 reductase activity
and SR 4317 formation, with higher values of enzyme activity
resulting in greater rates ofmetabolism. When similarexperiments
were carried out in air, no metabolism was detected.
Comparative activity of P450 reductase in human
breast cancer cell lines, the transfected clonal lines and
clinical breast tumour biopsy samples
A panel of five in vitro human breast cancer cell lines exhibiting
a range of endogenous P450 reductase activity (Patterson et al,
1995) and four ofthe generated clonal lines (Rd-06, Rd-09, Rd-16
and Rd-42) were used to generate both whole-cell lysates (S-9)
and whole-membrane fractions. As whole-membrane fractions are
routinely prepared from all surgical breast biopsy samples for
receptor analysis in other studies, we prepared, in an identical
manner, membrane preparations from the panel ofbreast cell lines
and four of the P450 reductase clonal lines. The activity of P450
reductase for both preparatory methods, in each clonal line,
correlates well (P = 0.007) with membrane fractions showing
an approximately a twofold higher level of activity (per mg of
protein) than the whole-cell lysates. The membrane fraction P450
reductase activities of each group of samples are plotted in Figure
6. The activities found in the range of P450 reductase clonal lines
is within and beyond that seen for both the in vitro cell lines and
the breast biopsy samples. A clear heterogeneity in functional
P450 reductase activity is seen in the breast biopsy samples, with
an 18-fold range in membrane-associated activity. Indeed, within
this limited group, 4 of the 14 samples have activities greater than
those found in the panel of unmodified breast cell lines. Further,
immunohistochemical analysis of a range of sections taken from
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each tumour biopsy demonstrated uniform immunoreactivity
localized to tumour epithelia (AV Patterson and TM Hacker,
unpublished data).
DISCUSSION
In this work, we have successfully transfected into the human
breast cancer MDA231 cell line a DNA construct encoding the
gene for the human form of P450 reductase. A panel of six stable
transfected clones were selected, which provided a 50-fold range
in activity ofP450 reductase. These cloned cells were then used to
provide information on the mechanism by which tirapazamine and
RSU1069 are activated to give cytotoxic species. For both agents,
under hypoxic conditions, P450 reductase was strongly implicated
in activation and subsequent toxicity, whereas, in air, expression of
reductase was only important for the toxicity of tirapazamine.
Consistent with the findings are the observations of Patterson et al
(1995) who showed, using a panel of human breast adenocarci-
noma cell lines, that metabolic reduction and toxicity of tira-
pazamine under hypoxic conditions was dependent upon cellular
expression of P450 reductase.
Transfectants overexpressing human P450 reductase have also
been established from a CHO cell line and these have been used to
assess the aerobic and hypoxic toxicity ofthe quinone bioreductive
drugs mitomycin (MMC) and porfiromycin (POR) (Belcourt et al,
1996). In the work of Belcourt et al'(1996), small but significant
increases in sensitivity to MMC and POR were seen in the trans-
fected clones under both oxygenated and hypoxic conditions, with
the increases in toxicity being greater under hypoxia than in air. In
the highest expressing clone (27-fold increase in P450 reductase
activity compared with wild type), the increases in toxicity ofboth
MMC and POR were about twofold (Belcourt et al, 1996). We
have evaluated the toxicity ofthese quinones in the MDA231 wild-
type cells and the transfected clones expressing the highest level of
P450 reductase (Rd53). Values of ICSO for cells exposed to MMC
or POR under hypoxic or aerobic conditions are given in Table 4.
For both drugs, there is a greater sensitivity in the high-expressing
clones, and this is seen both in air and hypoxia, which is entirely
consistent with the observations of Belcourt et al (1996).
In previous studies on the metabolism of tirapazamine (Walton
et al, 1989, 1992; Lloyd et al, 1991; Wang et al, 1993), it was
shown that both cytochrome P450 and cytochrome P450 reductase
contribute to the overall reduction of tirapazamine to its two-
electron reduced product SR4317. Cytochrome P450 is dependent
upon the presence of cytochrome P450 reductase for its catalytic
activity (Peterson and Prough, 1986), hence P450 reductase will
play both direct and indirect roles in the reduction oftirapazamine.
Lloyd et al (1991) identified a free-radical intermediate formed
during microsomal reduction of tirapazamine and they demon-
strated, through the use of appropriate inhibitors, that P450 reduc-
tase was the enzyme responsible for radical production. Moreover,
tirapazamine is reduced by purified rat liver cytochrome P450
reductase (Walton et al, 1989; Cahill and White, 1990), leading to
the production of strand breaks in co-incubated plasmid DNA
(Fitzsimmons et al, 1994). Measurement of SR4317 production,
after incubation of lysates of the different clones with tirapaza-
mine under hypoxic conditions, is a surrogate measure for the
formation of the tirapazamine radical (Patterson et al, 1995).
SR4317 can be formed by disproportionation of the tirapazamine
radical or by an oxidizing reaction of the radical with bio-mole-
cules (Baker et al, 1988; Laderoute et al, 1988). The formation of
SR4317 correlates with P450 reductase activity (Figure 5) and,
further, the production ofSR4317 also correlates with the hypoxic
toxicity of tirapazamine towards the different clones of MDA231
cells (P < 0.05). This strongly implicates P450 reductase-driven
activation oftirapazamine to its one-electron reduced radical as an
important contributory factor to the hypoxic toxicity of this drug,
and this is consistent with our previous studies using a range of
breast cancer cell lines. In contrast, Siim et al (1996) have exam-
ined the hypoxic metabolism of tirapazamine by a variety of
human and rodent cell lines of diverse histological type and
showed that SR4317 formation correlated poorly with toxicity,
whereas loss of tirapazamine was significantly related to drug
potency. However, the reductive metabolic routes that could result
in loss oftirapazamine and generate a radical (to give DNA strand
breaks and toxicity) without subsequent production of SR4317
were not discussed. It is of interest to note that SR4317 is not
metabolized when incubated with breast cancer cell lysates in
hypoxia (EC Chinjie and H Barham, unpublished data) and that
SR4330, the four-electron reduced product was not detected in the
metabolism studies reported here or by Patterson et al (1995) or
Siim et al (1996).
SR4317 can also be formed by direct two-electron reduction of
tirapazamine by DT-diaphorase (Riley and Workman, 1992), thus
bypassing the tirapazamine radical. However, it has been shown
that large differences in intracellular DT-diaphorase activity have
little, ifany, impact on tirapazamine toxicity (Patterson et al, 1994;
Plumb et al, 1994). In addition, results from the present work indi-
cate that formation of SR4317 is not detected when lysates of the
MDA231 transfectants are incubated with tirapazamine in air. This
has important mechanistic implications in view of the fact that the
toxicity of tirapazamine in air (3-h exposure) towards the clones
expressing the highest activities ofP450 reductase (Rd-42 and Rd-
53) shows a close similarity to that of wild-type MDA231 cells
exposed to tirapazamine in hypoxia. SR4317 is detected in lysates
of the latter exposed to tirapazamine in hypoxia but not after
incubation of Rd-42 or Rd-53 lysates with tirapazamine in air. As
indicated above, in breast cancer cells, formation of SR4317 is
consistent with radical formation and subsequent hypoxic toxicity.
The lack of SR4317 formation in air suggests that mechanism(s)
not involving the tirapazamine radical must be operational for
toxicity in air. However, under aerobic conditions, there is still a
significant dependence on P450 reductase activity for toxicity.
Therefore, our hypothesis for the mechanism underlying aerobic
toxicity is that redox cycling occurs, i.e. the reductase-dependent
continuous production of oxygen radicals in the presence of
tirapazamine. This hypothesis is currently being tested.
The metabolism of RSU1069 has not been studied; however, for
2-nitroimidazoles generally, benznidazole and misonidazole have
been used as model drugs (Mason and Holtzman, 1975; Walton and
Workman, 1987). Using rat liver microsomes it has been shown
that, in hypoxia, P450 reductase is important for conversion ofthe
nitro compound to the corresponding nitro radical anion, which is
a prerequisite for downstream conversion to the nitroso and
hydroxylamino analogues - thought to be the toxic, alkylating
species (Noss et al, 1988). The toxicity ofRSU1069 in air is due to
the presence ofthe monofunctional aziridine group in the Ni side-
chain of the molecule (Silver and O'Neill 1986; Stratford et al,
1986a), whereas, in hypoxia, reduction ofthe nitro group converts
RSU1069 to a bi-functional alkylating agent (Stratford et al, 1986a
and b, Whitmore and Gulyas, 1986; O'Neill et al, 1987). Therein
lies the basis for the differential hypoxic cell toxicity ofRSU1069.
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In the panel ofhuman tumour cell lines described by Houlbrook et
al (1994) and Robertson et al (1994), the values ofdifferential toxi-
city for RSU 1069 (IC50 air/IC50 nitrogen) vary from 1.6 to 75 (MA
Stephens and IJ Stratford, unpublished data). A significant contrib-
utory factor to this variation is likely to be the relative cellular
sensitivity to monofunctional vs bifunctional damage. The MDA
231 wild-type cells have the lowest differential toxicity; neverthe-
less, using this cell type with its transfected clones allows examina-
tion of the importance of P450 reductase for hypoxic activation of
2-nitroimidazoles, with RSU 1069 being used as an example. In air,
there is no dependence on P450 reductase for toxicity (Figures 2B
and 4), as would be expected if toxicity was due only to mono-
alkylation via the aziridine group. In contrast, underhypoxic condi-
tions, increased reduction of the nitro group (as a consequence of
higher P450 reductase activity) leads to increased toxicity.
Biopsies of human breast cancer have shown that high levels
of P450 reductase activity can be detected in these tumours and
that immunoreactivity is distributed throughout the neoplastic
epithelia. This, together with the demonstration that P450 reduc-
tase is a major determinant in controlling the toxicity of tirapaza-
mine and other bioreductive drugs, suggests that breast cancer may
be appropriate for treatment with such agents. However, such an
approach should initially only be carried out when an assessment
has been made of tumour activity of P450 reductase to identify
those patients whose tumours are most likely to respond to treat-
ment. In the case oftirapazamine, this could be accompanied by an
in vitro evaluation ofthe DNA-damaging effects ofthe drug by use
of the comet assay (Siim et al, 1996), although variations in
cellular ability to repair DNA damage could confound interpreta-
tion (Keohane et al, 1990; Beiderman et al, 1991). Tirapazamine
has successfully completed phase I and II clinical trials. It is clearly
dependent for activity on the presence ofboth tumour hypoxia and
P450 reductase, and these facts should be taken into account in the
future design oftrials and the application ofthis drug in the clinic.
Finally, the findings also suggest an opportunity for the application
of physiologically based gene therapy. Introduction, into tumours,
of P450 reductase as a therapeutic gene under the controls of
hypoxia responsive elements will increase gene expression in the
hypoxic regions of tumours and thereby increase the effectiveness
ofbioreductive drugs (Dachs et al, 1995).
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